A Study of the Efficacy and Safety of Combination Therapy of XELOX and Bevacizumab for Elderly Patients in Over the Age of 75 with Advanced or Recurrent Colorectal Cancer.

Abstract

We investigated the efficacy and safety of combination therapy of XELOX and Bevaci-zumab in late-stage elderly patients with advanced or recurrent colorectal cancer.

We report the result including a few case presentation. 12 patients who received XELOX and Bevacizumab therapy for 3 cycle or more in our hospital were evaluated.

After first treatment, the response rate in all patients was 50% and the disease control rate was 58.3%（CR：1/12, PR：5/12, NC：1/12, PD：5/12）．But 6 months later, the response rate was decreased to 8.3%. 5 cases were found to be ineffective in first treatment of this regimen, so next another chemotherapy were administered to

them, but 4 of 5 were found to be ineffective and followed best supportive care. On the other hand 1 of 5 was found to be partial response. 7 cases were found to be effective, but 5 of 7 were obliged to be interrupted chemotherapy due to general fatigue or anorexia, and all of 5 were found to be progressive disease in 6 months later of first treatment. In over the age of 80, the response rate was 42.3%（3/7），the desease control rate was 42.3%（3/7）．Bevacizumab and XELOX therapy was effective in elderly patients with advanced or recurrent colorectal cancer. It is very important to manage the side effects for continuity of chemotherapy.